IdeS Treatment Serum and Plasma Samples

Serum samples (blood collected with modified CAT serum vacutainer tubes (BD Diagnostics, Franklin Lakes, NJ) containing 2 mm iodoacetic acid) from healthy individuals treated with IdeS were from the Phase I trial NCT01802697 (23 (link)). Briefly, subjects were intravenously injected with IdeS (at the following doses: 0.01, 0.04, 0.12, or 0.24 mg IdeS/kg bodyweight), followed by a time-course collection of serum samples. Plasma samples from septic patients were from (48 (link)) (blood collected with vacutainer sodium citrate tubes). Plasma samples from healthy individuals were from (49 (link)) (blood collected with vacutainer sodium citrate tubes) or were purchased from Innovative Research (pooled normal human plasma, Novi, MI). Swabs and scrapes from local infections from patients with diagnosed S. pyogenes infection were collected at Skåne University Hospital or at Laurentiikliniken (a primary health clinic), both in Lund, Sweden. Tonsillar swabs from healthy individuals were obtained at Lund University, Lund Sweden. The medical ethics committee of Lund University approved this study (protocol numbers 2005/790 and 2015/14) and informed consent was obtained from all subjects. The samples were transported at −20 °C and stored at −80 °C until further processing. A compilation of patients, control and IdeS clinical phase I study samples is in supplemental Table S1.